Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Uterine Neoplasms | 15 | 2024 | 253 | 7.050 |
Why?
|
Ovarian Neoplasms | 12 | 2023 | 779 | 3.720 |
Why?
|
Sex Cord-Gonadal Stromal Tumors | 6 | 2023 | 19 | 3.240 |
Why?
|
Biomarkers, Tumor | 16 | 2024 | 1564 | 3.190 |
Why?
|
Endometrial Neoplasms | 7 | 2023 | 209 | 2.880 |
Why?
|
Carcinoma, Endometrioid | 6 | 2023 | 49 | 2.630 |
Why?
|
Neoplasms, Muscle Tissue | 4 | 2024 | 13 | 2.560 |
Why?
|
Perivascular Epithelioid Cell Neoplasms | 3 | 2021 | 9 | 2.080 |
Why?
|
Immunohistochemistry | 15 | 2024 | 1807 | 2.070 |
Why?
|
DNA Mismatch Repair | 4 | 2023 | 58 | 1.520 |
Why?
|
Genital Neoplasms, Female | 3 | 2022 | 110 | 1.490 |
Why?
|
Adenocarcinoma, Clear Cell | 4 | 2022 | 61 | 1.460 |
Why?
|
Myofibroma | 2 | 2020 | 4 | 1.290 |
Why?
|
Female | 47 | 2024 | 47284 | 1.250 |
Why?
|
Colorectal Neoplasms, Hereditary Nonpolyposis | 2 | 2022 | 47 | 1.240 |
Why?
|
Adenoma | 2 | 2022 | 251 | 1.230 |
Why?
|
Adnexal Diseases | 2 | 2019 | 16 | 1.130 |
Why?
|
Carcinoma | 3 | 2022 | 438 | 1.120 |
Why?
|
Peutz-Jeghers Syndrome | 2 | 2024 | 9 | 1.120 |
Why?
|
Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 3 | 2021 | 53 | 1.070 |
Why?
|
Lymphoma, B-Cell, Marginal Zone | 2 | 2016 | 23 | 1.010 |
Why?
|
Sarcoma, Endometrial Stromal | 2 | 2023 | 8 | 1.000 |
Why?
|
Rhabdomyosarcoma, Embryonal | 2 | 2022 | 6 | 0.950 |
Why?
|
Teratoma | 2 | 2023 | 53 | 0.930 |
Why?
|
Endometrial Stromal Tumors | 2 | 2023 | 5 | 0.930 |
Why?
|
Neoplasms, Germ Cell and Embryonal | 2 | 2023 | 52 | 0.920 |
Why?
|
Nuclear Receptor Coactivator 2 | 2 | 2021 | 16 | 0.900 |
Why?
|
Humans | 48 | 2024 | 91235 | 0.870 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2024 | 105 | 0.860 |
Why?
|
Adenocarcinoma | 2 | 2022 | 1184 | 0.850 |
Why?
|
Leiomyoma | 2 | 2017 | 204 | 0.820 |
Why?
|
Broad Ligament | 1 | 2022 | 1 | 0.800 |
Why?
|
Neoplasms, Adnexal and Skin Appendage | 1 | 2022 | 2 | 0.800 |
Why?
|
Ribonuclease III | 2 | 2022 | 16 | 0.790 |
Why?
|
Middle Aged | 24 | 2024 | 26618 | 0.790 |
Why?
|
Adult | 22 | 2024 | 27215 | 0.770 |
Why?
|
DEAD-box RNA Helicases | 2 | 2022 | 65 | 0.760 |
Why?
|
Leiomyosarcoma | 1 | 2022 | 46 | 0.760 |
Why?
|
Krukenberg Tumor | 2 | 2018 | 3 | 0.750 |
Why?
|
Smooth Muscle Tumor | 1 | 2021 | 5 | 0.750 |
Why?
|
Fibronectins | 1 | 2021 | 102 | 0.720 |
Why?
|
Angiofibroma | 1 | 2020 | 4 | 0.710 |
Why?
|
Vulvar Neoplasms | 1 | 2020 | 19 | 0.710 |
Why?
|
Myxoma | 1 | 2020 | 30 | 0.700 |
Why?
|
Glioma | 1 | 2023 | 295 | 0.700 |
Why?
|
In Situ Hybridization, Fluorescence | 2 | 2018 | 356 | 0.700 |
Why?
|
Polyps | 1 | 2020 | 29 | 0.690 |
Why?
|
DNA-Binding Proteins | 5 | 2023 | 1248 | 0.690 |
Why?
|
MutS Homolog 2 Protein | 2 | 2019 | 33 | 0.670 |
Why?
|
Protein-Tyrosine Kinases | 1 | 2021 | 307 | 0.670 |
Why?
|
Adnexa Uteri | 1 | 2019 | 11 | 0.660 |
Why?
|
Diagnosis, Differential | 8 | 2024 | 1610 | 0.660 |
Why?
|
Soft Tissue Neoplasms | 1 | 2020 | 129 | 0.660 |
Why?
|
Aged | 16 | 2024 | 19604 | 0.650 |
Why?
|
Molecular Diagnostic Techniques | 1 | 2019 | 72 | 0.630 |
Why?
|
Carcinoma, Signet Ring Cell | 1 | 2018 | 9 | 0.620 |
Why?
|
Epithelioid Cells | 1 | 2018 | 13 | 0.620 |
Why?
|
Fumarate Hydratase | 1 | 2017 | 6 | 0.570 |
Why?
|
Proto-Oncogene Proteins | 1 | 2021 | 668 | 0.570 |
Why?
|
Carcinoma, Ductal, Breast | 1 | 2018 | 160 | 0.550 |
Why?
|
Breast Neoplasms | 2 | 2022 | 3033 | 0.530 |
Why?
|
Progestins | 1 | 2016 | 22 | 0.520 |
Why?
|
DNA Repair Enzymes | 1 | 2016 | 55 | 0.510 |
Why?
|
Nuclear Proteins | 2 | 2021 | 731 | 0.500 |
Why?
|
Giant Cell Tumors | 1 | 2015 | 3 | 0.500 |
Why?
|
Mismatch Repair Endonuclease PMS2 | 3 | 2023 | 24 | 0.500 |
Why?
|
MutL Protein Homolog 1 | 3 | 2023 | 35 | 0.500 |
Why?
|
Ovary | 2 | 2021 | 263 | 0.490 |
Why?
|
Pregnancy Complications, Neoplastic | 1 | 2015 | 28 | 0.490 |
Why?
|
Adenosine Triphosphatases | 1 | 2016 | 155 | 0.490 |
Why?
|
Ataxia Telangiectasia | 1 | 2015 | 11 | 0.490 |
Why?
|
Premenopause | 1 | 2015 | 57 | 0.480 |
Why?
|
Parotid Gland | 1 | 2015 | 30 | 0.470 |
Why?
|
Young Adult | 7 | 2024 | 6522 | 0.470 |
Why?
|
Epstein-Barr Virus Infections | 1 | 2015 | 55 | 0.460 |
Why?
|
Postmenopause | 1 | 2015 | 102 | 0.460 |
Why?
|
Herpesvirus 4, Human | 1 | 2015 | 120 | 0.460 |
Why?
|
Adaptor Proteins, Signal Transducing | 1 | 2016 | 316 | 0.450 |
Why?
|
Testosterone | 1 | 2015 | 272 | 0.450 |
Why?
|
Skin Diseases | 1 | 2015 | 174 | 0.440 |
Why?
|
Prognosis | 8 | 2022 | 3829 | 0.430 |
Why?
|
Neoplasm Grading | 1 | 2015 | 379 | 0.420 |
Why?
|
Predictive Value of Tests | 3 | 2024 | 1748 | 0.380 |
Why?
|
Sarcoma | 2 | 2024 | 217 | 0.360 |
Why?
|
Adolescent | 5 | 2024 | 9435 | 0.340 |
Why?
|
Tumor Burden | 2 | 2024 | 312 | 0.340 |
Why?
|
Child | 4 | 2024 | 7291 | 0.340 |
Why?
|
Aged, 80 and over | 5 | 2021 | 6844 | 0.340 |
Why?
|
Urethral Stricture | 2 | 2019 | 14 | 0.330 |
Why?
|
Gene Fusion | 2 | 2020 | 41 | 0.330 |
Why?
|
Mutation | 4 | 2021 | 4210 | 0.320 |
Why?
|
Uterine Cervical Neoplasms | 2 | 2022 | 300 | 0.310 |
Why?
|
Gene Rearrangement | 2 | 2020 | 177 | 0.290 |
Why?
|
Neoplasm Recurrence, Local | 2 | 2024 | 1378 | 0.280 |
Why?
|
Papillomavirus Infections | 2 | 2022 | 277 | 0.260 |
Why?
|
Biopsy | 3 | 2019 | 1195 | 0.250 |
Why?
|
Cervix Uteri | 3 | 2022 | 71 | 0.230 |
Why?
|
Oncogene Fusion | 2 | 2021 | 9 | 0.230 |
Why?
|
Tissue Array Analysis | 2 | 2021 | 127 | 0.220 |
Why?
|
Kaplan-Meier Estimate | 2 | 2016 | 853 | 0.210 |
Why?
|
Necrosis | 1 | 2023 | 210 | 0.210 |
Why?
|
Incidence | 2 | 2019 | 1599 | 0.210 |
Why?
|
Lichen Sclerosus et Atrophicus | 2 | 2019 | 7 | 0.210 |
Why?
|
Gene Deletion | 1 | 2024 | 345 | 0.210 |
Why?
|
Adenosarcoma | 1 | 2022 | 3 | 0.200 |
Why?
|
Neoplastic Syndromes, Hereditary | 1 | 2022 | 20 | 0.200 |
Why?
|
Wolffian Ducts | 1 | 2022 | 7 | 0.200 |
Why?
|
Phenotype | 2 | 2019 | 2489 | 0.200 |
Why?
|
Solitary Fibrous Tumors | 1 | 2022 | 5 | 0.200 |
Why?
|
Endometrial Hyperplasia | 1 | 2022 | 11 | 0.200 |
Why?
|
Hemorrhage | 1 | 2023 | 289 | 0.190 |
Why?
|
Alphapapillomavirus | 1 | 2022 | 45 | 0.190 |
Why?
|
Cystadenoma, Papillary | 1 | 2021 | 9 | 0.190 |
Why?
|
SMARCB1 Protein | 1 | 2021 | 13 | 0.180 |
Why?
|
Nuclear Receptor Coactivator 1 | 1 | 2021 | 24 | 0.180 |
Why?
|
Myeloid Ecotropic Viral Integration Site 1 Protein | 1 | 2021 | 20 | 0.180 |
Why?
|
Neoplasms, Connective and Soft Tissue | 1 | 2020 | 4 | 0.180 |
Why?
|
Urogenital Neoplasms | 1 | 2021 | 24 | 0.180 |
Why?
|
Genitalia, Female | 1 | 2020 | 25 | 0.180 |
Why?
|
Vulva | 1 | 2020 | 23 | 0.180 |
Why?
|
Oncogene Proteins, Fusion | 1 | 2021 | 134 | 0.180 |
Why?
|
DNA Helicases | 1 | 2021 | 85 | 0.170 |
Why?
|
Immunophenotyping | 1 | 2020 | 218 | 0.170 |
Why?
|
Genetic Predisposition to Disease | 2 | 2019 | 2383 | 0.170 |
Why?
|
Papillomaviridae | 2 | 2022 | 168 | 0.170 |
Why?
|
Urologic Surgical Procedures, Male | 1 | 2019 | 15 | 0.170 |
Why?
|
Gene Dosage | 1 | 2019 | 210 | 0.160 |
Why?
|
Neoplasm Staging | 3 | 2022 | 2024 | 0.150 |
Why?
|
Urethra | 1 | 2019 | 116 | 0.150 |
Why?
|
Pregnancy | 2 | 2016 | 3086 | 0.150 |
Why?
|
Mitosis | 1 | 2018 | 152 | 0.150 |
Why?
|
Carcinoma, Renal Cell | 1 | 2021 | 333 | 0.140 |
Why?
|
Retrospective Studies | 3 | 2023 | 9401 | 0.140 |
Why?
|
Genomics | 1 | 2023 | 804 | 0.140 |
Why?
|
Boston | 1 | 2016 | 37 | 0.130 |
Why?
|
Immunoglobulin Heavy Chains | 1 | 2016 | 133 | 0.130 |
Why?
|
Uterine Cervical Dysplasia | 1 | 2016 | 34 | 0.130 |
Why?
|
Salpingectomy | 1 | 2015 | 3 | 0.130 |
Why?
|
Penicillamine | 1 | 2015 | 12 | 0.130 |
Why?
|
Voice Disorders | 1 | 2015 | 7 | 0.130 |
Why?
|
California | 1 | 2016 | 152 | 0.130 |
Why?
|
Elastic Tissue | 1 | 2015 | 18 | 0.130 |
Why?
|
Alopecia | 1 | 2015 | 34 | 0.130 |
Why?
|
Luteinization | 1 | 2015 | 1 | 0.130 |
Why?
|
Hirsutism | 1 | 2015 | 61 | 0.120 |
Why?
|
Ovariectomy | 1 | 2015 | 83 | 0.120 |
Why?
|
Inflammation | 1 | 2021 | 1003 | 0.120 |
Why?
|
Hyperplasia | 1 | 2015 | 153 | 0.120 |
Why?
|
Septum of Brain | 2 | 2005 | 2 | 0.120 |
Why?
|
Stromal Cells | 1 | 2016 | 151 | 0.120 |
Why?
|
Antirheumatic Agents | 1 | 2015 | 60 | 0.120 |
Why?
|
Scleroderma, Systemic | 1 | 2015 | 56 | 0.120 |
Why?
|
Ovarian Diseases | 1 | 2015 | 32 | 0.120 |
Why?
|
Neoplasms, Cystic, Mucinous, and Serous | 1 | 2015 | 16 | 0.120 |
Why?
|
Fibroma | 1 | 2015 | 33 | 0.120 |
Why?
|
Parasympathetic Nervous System | 2 | 2005 | 36 | 0.120 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 1 | 2016 | 137 | 0.120 |
Why?
|
Hypoglycemia | 1 | 2015 | 110 | 0.120 |
Why?
|
Estradiol | 1 | 2015 | 250 | 0.120 |
Why?
|
Endometriosis | 1 | 2015 | 59 | 0.120 |
Why?
|
Extremities | 1 | 2015 | 178 | 0.110 |
Why?
|
Risk Factors | 1 | 2024 | 5609 | 0.110 |
Why?
|
Pregnancy Complications | 1 | 2016 | 345 | 0.100 |
Why?
|
Transcription Factors | 1 | 2021 | 1672 | 0.100 |
Why?
|
Reproducibility of Results | 1 | 2018 | 2788 | 0.100 |
Why?
|
Insulin | 1 | 2015 | 1162 | 0.090 |
Why?
|
Axotomy | 2 | 2005 | 8 | 0.080 |
Why?
|
Time Factors | 1 | 2016 | 5385 | 0.070 |
Why?
|
Capsid Proteins | 1 | 2005 | 32 | 0.060 |
Why?
|
Nerve Growth Factors | 1 | 2005 | 63 | 0.060 |
Why?
|
Polyethyleneimine | 1 | 2004 | 7 | 0.060 |
Why?
|
Nerve Growth Factor | 1 | 2004 | 18 | 0.060 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2015 | 2551 | 0.060 |
Why?
|
Genetic Vectors | 1 | 2005 | 448 | 0.060 |
Why?
|
Gene Transfer Techniques | 1 | 2004 | 153 | 0.050 |
Why?
|
Follow-Up Studies | 2 | 2022 | 3723 | 0.050 |
Why?
|
Male | 5 | 2021 | 43375 | 0.050 |
Why?
|
Co-Repressor Proteins | 1 | 2023 | 25 | 0.050 |
Why?
|
Biomarkers | 2 | 2019 | 1822 | 0.050 |
Why?
|
Von Hippel-Lindau Tumor Suppressor Protein | 1 | 2021 | 19 | 0.050 |
Why?
|
Uterus | 1 | 2023 | 222 | 0.050 |
Why?
|
DNA Mutational Analysis | 1 | 2022 | 532 | 0.040 |
Why?
|
beta Catenin | 1 | 2022 | 267 | 0.040 |
Why?
|
Microscopy, Electron | 1 | 2021 | 511 | 0.040 |
Why?
|
Point Mutation | 1 | 2021 | 246 | 0.040 |
Why?
|
Repressor Proteins | 1 | 2023 | 430 | 0.040 |
Why?
|
Preoperative Period | 1 | 2019 | 95 | 0.040 |
Why?
|
Sequence Analysis, DNA | 1 | 2021 | 874 | 0.040 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2021 | 494 | 0.040 |
Why?
|
Case-Control Studies | 1 | 2022 | 1883 | 0.030 |
Why?
|
Protein Biosynthesis | 1 | 2019 | 390 | 0.030 |
Why?
|
Reoperation | 1 | 2019 | 611 | 0.030 |
Why?
|
Papanicolaou Test | 1 | 2016 | 38 | 0.030 |
Why?
|
Recurrence | 1 | 2019 | 1171 | 0.030 |
Why?
|
Vaginal Smears | 1 | 2016 | 70 | 0.030 |
Why?
|
Neurons | 1 | 2004 | 1599 | 0.030 |
Why?
|
Vagina | 1 | 2016 | 176 | 0.030 |
Why?
|
Stereotaxic Techniques | 2 | 2005 | 80 | 0.030 |
Why?
|
Risk Assessment | 1 | 2022 | 2344 | 0.030 |
Why?
|
Green Fluorescent Proteins | 2 | 2005 | 308 | 0.030 |
Why?
|
Gene Expression Profiling | 1 | 2019 | 1473 | 0.030 |
Why?
|
Rats, Sprague-Dawley | 2 | 2005 | 1230 | 0.020 |
Why?
|
Prospective Studies | 1 | 2019 | 4374 | 0.020 |
Why?
|
Rats | 2 | 2005 | 4060 | 0.020 |
Why?
|
Treatment Outcome | 1 | 2019 | 8429 | 0.020 |
Why?
|
Fornix, Brain | 1 | 2005 | 2 | 0.020 |
Why?
|
Choline O-Acetyltransferase | 1 | 2005 | 23 | 0.020 |
Why?
|
Genes, Reporter | 1 | 2005 | 275 | 0.010 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2005 | 375 | 0.010 |
Why?
|
Indicators and Reagents | 1 | 2004 | 71 | 0.010 |
Why?
|
Luminescent Proteins | 1 | 2004 | 144 | 0.010 |
Why?
|
Transgenes | 1 | 2004 | 185 | 0.010 |
Why?
|
Animals | 2 | 2005 | 27852 | 0.010 |
Why?
|
Mice | 1 | 2004 | 12029 | 0.010 |
Why?
|